Exhibit 99.1
Venus Concept Announces Second Quarter of Fiscal Year 2023 Financial Results
TORONTO, August 14, 2023 (GLOBE NEWSWIRE) –
Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2023.
Second Quarter 2023 Summary & Recent Progress:
| • |
Company continues to execute against Transformational Plan
|
| ➢ |
Total revenue of $20.1 million, down $7.2 million, or 26%, year-over-year
|
| ➢ |
Cash system revenue represented approximately 74% of total systems and subscriptions revenue, compared to 49% in the prior year period
|
| ➢ |
Operating expenses of $20 million, including approximately $0.4 million of costs related to restructuring activities, down $6.2 million, or 24%, year-over-year
|
| ➢ |
Cash used in operations of $2.1 million, down 71% year-over-year
|
| ➢ |
GAAP net loss attributable to stockholders of $7.4 million, down $3.2 million, or 30% year-over-year and down $2.3 million, or 24%, quarter-over-quarter
|
| ➢ |
Adjusted EBITDA loss of $4.0 million, down $1.5 million, or 27% year-over-year
|
| • |
On May 11, 2023, the Company announced a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock, which began trading on The Nasdaq Capital Market on a split-adjusted
basis at the open of trading on May 12, 2023.
|
| • |
On May 15, 2023, the Company announced that it entered into a stock purchase agreement with funds affiliated with EW Healthcare Partners for a multi-tranche private placement of senior convertible
preferred stock for maximum gross proceeds of up to $9,000,000.
|
| • |
On July 13, 2023, the Company announced the establishment of a medical advisory board for AI.ME, its next generation robotic platform. The medical advisory board will provide strategic input,
guidance, and clinical recommendation regarding AI.ME, which received its first 510(k) clearance from the U.S. Food and Drug Administration in December 2022 for fractional skin resurfacing.
|
Management Commentary:
“Our second quarter revenue results were in-line with the Company’s expectations,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “2023 is a year of
re-focusing the business and repositioning Venus Concept to enhance the cash flow profile of the Company and to accelerate the path to long-term, sustainable, profitability and growth. To that end, we are encouraged by the continued progress
towards our restructuring activities designed to improve our operations and cost structure, and our continued strategic shift to prioritize cash system sales which together drove a 73% year-over-year reduction in cash used in operations in Q2. We
remain highly focused on maximizing our capital resources as we work to manage our near-to-intermediate-term debt obligations and to further enhance the Company’s foundation for achieving our longer-term goals. We value the constructive approach
that our primary lenders are taking in supporting the company through this transition.”
Second Quarter of 2023 Revenue by Region and by Product Type:
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
(dollars in thousands)
|
(dollars in thousands)
|
|||||||||||||||
|
Revenues by region:
|
||||||||||||||||
|
United States
|
$
|
9,757
|
$
|
13,416
|
$
|
20,498
|
$
|
26,545
|
||||||||
|
International
|
10,318
|
13,850
|
20,108
|
27,127
|
||||||||||||
|
Total revenue
|
$
|
20,075
|
$
|
27,266
|
$
|
40,606
|
$
|
53,672
|
||||||||
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
(dollars in thousands)
|
(dollars in thousands)
|
|||||||||||||||
|
Revenues by product:
|
||||||||||||||||
|
Subscription—Systems
|
$
|
4,311
|
$
|
11,874
|
$
|
10,072
|
$
|
22,297
|
||||||||
|
Products—Systems
|
12,313
|
11,548
|
23,377
|
23,422
|
||||||||||||
|
Products—Other (1)
|
2,586
|
3,080
|
5,533
|
6,577
|
||||||||||||
|
Services
|
865
|
764
|
1,624
|
1,376
|
||||||||||||
|
Total revenue
|
$
|
20,075
|
$
|
27,266
|
$
|
40,606
|
$
|
53,672
|
||||||||
(1) Products-Other include ARTAS procedure kits, Viva tips and other consumables.
Second Quarter 2023 Financial Results:
|
Three Months Ended June 30,
|
||||||||||||||||||||||||
|
2023
|
2022
|
Change
|
||||||||||||||||||||||
|
(in thousands, except percentages)
|
$ |
% of Total
|
$ |
% of Total
|
$ |
%
|
||||||||||||||||||
|
Revenues:
|
||||||||||||||||||||||||
|
Subscription—Systems
|
$
|
4,311
|
21.5
|
$
|
11,874
|
43.5
|
$
|
(7,563
|
)
|
(63.7
|
)
|
|||||||||||||
|
Products—Systems
|
12,313
|
61.3
|
11,548
|
42.4
|
765
|
6.6
|
||||||||||||||||||
|
Products—Other
|
2,586
|
12.9
|
3,080
|
11.3
|
(494
|
)
|
(16.0
|
)
|
||||||||||||||||
|
Services
|
865
|
4.3
|
764
|
2.8
|
101
|
13.2
|
||||||||||||||||||
|
Total
|
$
|
20,075
|
100.0
|
$
|
27,266
|
100.0
|
$
|
(7,191
|
)
|
(26.4
|
)
|
|||||||||||||
Total revenue for the second quarter of 2023 decreased $7.2 million, or 26%, to $20.1 million, compared to the second quarter of 2022. The decrease in total revenue,
by region, was driven by a 27% decrease year-over-year in United States revenue and a 26% decrease year-over-year in international revenue. The decrease in total revenue, by product category, was driven by a 64% decrease in lease revenue and a 16%
decrease in products - other revenue, offset partially by a 7% increase in products – systems revenue and a 13% increase in services revenue. The percentage of total systems revenue derived from the Company’s subscription model was approximately
26% in the second quarter of 2023, compared to 51% in the prior year period.
Gross profit for the second quarter of 2023 decreased $4.8 million, or 25%, to $14.2 million compared to the second quarter of 2022. The change in gross profit was
driven primarily by the year-over-year decline in revenue in the United States and International markets driven by the strategic decision to deemphasize subscription sales and the exit from unprofitable direct markets. Gross margin was 70.8% of
revenue, compared to 69.9% of revenue for the second quarter of 2022. The change in gross margin was primarily due to changes in product mix, including lower ARTAS systems sales which have a lower gross margin than our energy-based devices, and a
$0.2 million foreign exchange headwind as a result of certain foreign currencies depreciating relative to the U.S. dollar.
Operating expenses for the second quarter of 2023 decreased $6.2 million, or 24%, to $20.0 million, compared to the second quarter of 2022. The change in total
operating expenses was driven by a decrease of $3.3 million, or 26%, in general and administrative expenses and a decrease of $2.1 million, or 20%, in sales and marketing expenses. Second quarter of 2023 general and administrative expenses include
approximately $0.4 million of costs related to restructuring activities designed to improve the Company's operations and cost structure.
Operating loss for the second quarter of 2023 was $5.8 million, compared to operating loss of $7.1 million for the second quarter of 2022.
Net loss attributable to stockholders for the second quarter of 2023 was $7.4 million, or $1.35 per share, compared to net loss of $10.6 million, or $2.47 per share
for the second quarter of 2022. Adjusted EBITDA loss for the second quarter of 2023 was $4.0 million, compared to adjusted EBITDA loss of $5.5 million for the second quarter of 2022.
As of June 30, 2023, the Company had cash and cash equivalents of $6.1 million and total debt obligations of approximately $78.4 million, compared to $11.6 million and
$77.7 million, respectively, as of December 31, 2022.
Fiscal Year 2023 Revenue Guidance:
The Company continues to expect total revenue for the twelve months ending December 31, 2023 in the range of $90.0 million to $95.0 million, representing a decrease in
the range of approximately 9.5% to 4.5%, year-over-year, compared to total revenue of $99.5 million for the twelve months ended December 31, 2022.
Conference Call Details:
Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2023 to discuss the results of the quarter with a question-and-answer session. Those who
would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13739854. A live webcast of the call will also be provided on the investor relations section of the Company's website at
ir.venusconcept.com.
For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13739854.
The webcast will be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and
hair restoration technologies and reach in over 60 countries and 14 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow,
Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading
healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section
21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as
“anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events
and future trends. These forward-looking statements include, but are not limited to, statements about our financial performance and metrics; the growth in demand for our systems and other products and sustainability thereof; and the efficacy of the
restructuring plan, workforce reduction and management transition. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and
management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our
forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, general economic conditions and
involve risks and uncertainties that may cause results to differ materially from those set forth in the statements and those risks and uncertainties described under Part II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I
Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on
the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking
statements to reflect new information or future events or otherwise.
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept Inc.
Condensed Consolidated Balance Sheets
(In thousands of U.S. dollars, except share and per share data)
|
June 30,
2023
|
December 31,
2022
|
|||||||
|
ASSETS
|
||||||||
|
CURRENT ASSETS:
|
||||||||
|
Cash and cash equivalents
|
$
|
6,122
|
$
|
11,569
|
||||
|
Accounts receivable, net of allowance of $13,233 and $13,619 as of June 30, 2023, and December 31, 2022, respectively
|
37,520
|
37,262
|
||||||
|
Inventories
|
22,936
|
23,906
|
||||||
|
Prepaid expenses
|
1,481
|
1,688
|
||||||
|
Advances to suppliers
|
5,749
|
5,881
|
||||||
|
Other current assets
|
1,984
|
3,702
|
||||||
|
Total current assets
|
75,792
|
84,008
|
||||||
|
LONG-TERM ASSETS:
|
||||||||
|
Long-term receivables, net
|
12,082
|
20,044
|
||||||
|
Deferred tax assets
|
876
|
947
|
||||||
|
Severance pay funds
|
586
|
741
|
||||||
|
Property and equipment, net
|
1,640
|
1,857
|
||||||
|
Operating right-of-use assets, net
|
4,983
|
5,862
|
||||||
|
Intangible assets
|
10,197
|
11,919
|
||||||
|
Total long-term assets
|
30,364
|
41,370
|
||||||
|
TOTAL ASSETS
|
$
|
106,156
|
$
|
125,378
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
CURRENT LIABILITIES:
|
||||||||
|
Trade payables
|
$
|
8,293
|
$
|
8,033
|
||||
|
Accrued expenses and other current liabilities
|
13,063
|
16,667
|
||||||
|
Current portion of long-term debt
|
7,735
|
7,735
|
||||||
|
Income taxes payable
|
434
|
117
|
||||||
|
Unearned interest income
|
1,915
|
2,397
|
||||||
|
Warranty accrual
|
880
|
1,074
|
||||||
|
Deferred revenues
|
1,050
|
1,765
|
||||||
|
Operating lease liabilities
|
1,571
|
1,807
|
||||||
|
Total current liabilities
|
34,941
|
39,595
|
||||||
|
LONG-TERM LIABILITIES:
|
||||||||
|
Long-term debt
|
70,683
|
70,003
|
||||||
|
Income tax payable
|
385
|
374
|
||||||
|
Deferred tax liabilities
|
6
|
—
|
||||||
|
Accrued severance pay
|
696
|
867
|
||||||
|
Unearned interest revenue
|
552
|
957
|
||||||
|
Warranty accrual
|
377
|
408
|
||||||
|
Operating lease liabilities
|
3,666
|
4,221
|
||||||
|
Other long-term liabilities
|
392
|
215
|
||||||
|
Total long-term liabilities
|
76,757
|
77,045
|
||||||
|
TOTAL LIABILITIES
|
111,698
|
116,640
|
||||||
|
Commitments and Contingencies (Note 9)
|
||||||||
|
STOCKHOLDERS’ EQUITY (Note 14):
|
||||||||
|
Common Stock, $0.0001 par value: 300,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 5,526,481 and 5,141,689 issued
and outstanding as of June 30, 2023, and December 31, 2022, respectively
|
30
|
29
|
||||||
|
Additional paid-in capital
|
235,468
|
232,169
|
||||||
|
Accumulated deficit
|
(241,719
|
)
|
(224,105
|
)
|
||||
|
TOTAL STOCKHOLDERS’ EQUITY
|
(6,221
|
)
|
8,093
|
|||||
|
Non-controlling interests
|
679
|
645
|
||||||
|
(5,542
|
)
|
8,738
|
||||||
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$
|
106,156
|
$
|
125,378
|
||||
The accompanying notes are an integral part of these consolidated financial statements.
Venus Concept Inc.
Condensed Consolidated Statements of Operations
(In thousands of U.S. dollars, except per share data)
|
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Revenue
|
||||||||||||||||
|
Leases
|
$
|
4,311
|
$
|
11,874
|
$
|
10,072
|
$
|
22,297
|
||||||||
|
Products and services
|
15,764
|
15,392
|
30,534
|
31,375
|
||||||||||||
|
20,075
|
27,266
|
40,606
|
53,672
|
|||||||||||||
|
Cost of goods sold:
|
||||||||||||||||
|
Leases
|
721
|
2,761
|
2,450
|
5,461
|
||||||||||||
|
Products and services
|
5,134
|
5,459
|
10,237
|
11,402
|
||||||||||||
|
5,855
|
8,220
|
12,687
|
16,863
|
|||||||||||||
|
Gross profit
|
14,220
|
19,046
|
27,919
|
36,809
|
||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling and marketing
|
8,380
|
10,523
|
16,412
|
21,607
|
||||||||||||
|
General and administrative
|
9,633
|
12,937
|
20,818
|
24,409
|
||||||||||||
|
Research and development
|
1,965
|
2,712
|
4,602
|
5,355
|
||||||||||||
|
Total operating expenses
|
19,978
|
26,172
|
41,832
|
51,371
|
||||||||||||
|
(Loss) from operations
|
(5,758
|
)
|
(7,126
|
)
|
(13,913
|
)
|
(14,562
|
)
|
||||||||
|
Other expenses:
|
||||||||||||||||
|
Foreign exchange loss (gain)
|
(178
|
)
|
2,370
|
(530
|
)
|
2,375
|
||||||||||
|
Finance expenses
|
1,553
|
1,034
|
3,061
|
1,957
|
||||||||||||
|
(Gain) loss on disposal of subsidiaries
|
(1
|
)
|
-
|
76
|
-
|
|||||||||||
|
Loss before income taxes
|
(7,132
|
)
|
(10,530
|
)
|
(16,520
|
)
|
(18,894
|
)
|
||||||||
|
Income tax (benefit) expense
|
189
|
(18
|
)
|
424
|
254
|
|||||||||||
|
Net loss
|
(7,321
|
)
|
(10,512
|
)
|
(16,944
|
)
|
(19,148
|
)
|
||||||||
|
Net loss attributable to stockholders of the Company
|
(7,409
|
)
|
(10,559
|
)
|
(17,066
|
)
|
(19,178
|
)
|
||||||||
|
Net income attributable to non-controlling interest
|
88
|
47
|
122
|
30
|
||||||||||||
|
Net loss per share:
|
||||||||||||||||
|
Basic
|
$
|
(1.35
|
)
|
$
|
(2.47
|
)
|
$
|
(3.19
|
)
|
$
|
(4.49
|
)
|
||||
|
Diluted
|
$
|
(1.35
|
)
|
$
|
(2.47
|
)
|
$
|
(3.19
|
)
|
$
|
(4.49
|
)
|
||||
|
Weighted-average number of shares used in per share calculation:
|
||||||||||||||||
|
Basic
|
5,471
|
4,276
|
5,355
|
4,271
|
||||||||||||
|
Diluted
|
5,471
|
4,276
|
5,355
|
4,271
|
||||||||||||
Venus Concept Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
|
Six Months Ended June 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
|
Net loss
|
$
|
(16,944
|
)
|
$
|
(19,148
|
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation and amortization
|
2,032
|
2,212
|
||||||
|
Stock-based compensation
|
850
|
1,001
|
||||||
|
Provision for expected credit losses
|
977
|
3,521
|
||||||
|
Provision for inventory obsolescence
|
343
|
862
|
||||||
|
Finance expenses and accretion
|
680
|
182
|
||||||
|
Deferred tax expense (recovery)
|
78
|
(283
|
)
|
|||||
|
Loss on sale of subsidiary
|
76
|
-
|
||||||
|
Loss on disposal of property and equipment
|
-
|
31
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable short-term and long-term
|
6,153
|
(2,492
|
)
|
|||||
|
Inventories
|
627
|
(2,682
|
)
|
|||||
|
Prepaid expenses
|
207
|
568
|
||||||
|
Advances to suppliers
|
132
|
(3,797
|
)
|
|||||
|
Other current assets
|
1,642
|
(115
|
)
|
|||||
|
Operating right-of-use assets, net
|
879
|
6,057
|
||||||
|
Other long-term assets
|
(268
|
)
|
(79
|
)
|
||||
|
Trade payables
|
259
|
2,361
|
||||||
|
Accrued expenses and other current liabilities
|
(4,185
|
)
|
(1,969
|
)
|
||||
|
Current operating lease liabilities
|
(236
|
)
|
(1,764
|
)
|
||||
|
Severance pay funds
|
154
|
2
|
||||||
|
Unearned interest income
|
(887
|
)
|
284
|
|||||
|
Long-term operating lease liabilities
|
(554
|
)
|
(4,293
|
)
|
||||
|
Other long-term liabilities
|
(25
|
)
|
(172
|
)
|
||||
|
Net cash used in operating activities
|
(8,010
|
)
|
(19,713
|
)
|
||||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
|
Purchases of property and equipment
|
(92
|
)
|
(251
|
)
|
||||
|
Net cash used in investing activities
|
(92
|
)
|
(251
|
)
|
||||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
|
2023 Multi-Tranche Private Placement, net of costs of $367
|
1,633
|
—
|
||||||
|
Proceeds from exercise of options
|
—
|
23
|
||||||
|
Proceeds from issuance of common stock
|
1,109
|
272
|
||||||
|
Repayment of government assistance loans
|
—
|
(543
|
)
|
|||||
|
Dividends from subsidiaries paid to non-controlling interest
|
(87
|
)
|
(124
|
)
|
||||
|
Net cash (used in) provided by financing activities
|
2,655
|
(372
|
)
|
|||||
|
NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
|
(5,447
|
)
|
(20,336
|
)
|
||||
|
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period
|
11,569
|
30,876
|
||||||
|
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period
|
$
|
6,122
|
$
|
10,540
|
||||
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
|
||||||||
|
Cash paid for income taxes
|
$
|
18
|
$
|
224
|
||||
|
Cash paid for interest
|
$
|
2,381
|
$
|
1,775
|
||||
Use of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP measure defined as net income (loss) before foreign exchange loss (gain), financial expenses, income tax expense (benefit),
depreciation and amortization, stock-based compensation and non-recurring items for a given period. Adjusted EBITDA is not a measure of our financial performance under U.S. GAAP and should not be considered an alternative to net income or any
other performance measures derived in accordance with U.S. GAAP. Accordingly, you should consider Adjusted EBITDA along with other financial performance measures, including net income, and our financial results presented in accordance with U.S.
GAAP. Other companies, including companies in our industry, may calculate Adjusted EBITDA differently or not at all, which reduces its usefulness as a comparative measure. We understand that although Adjusted EBITDA is frequently used by
securities analysts, lenders and others in their evaluation of companies, Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S.
GAAP. Some of these limitations are: Adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments; Adjusted EBITDA does not reflect changes in, or cash requirements for, our
working capital needs; and although depreciation and amortization are non-cash charges, the assets being depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.
We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from
period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the U.S. dollar, tax positions (such as the
impact on periods or companies of changes in effective tax rates), the age and book depreciation of fixed assets (affecting relative depreciation expense), amortization of intangible assets, stock-based compensation expense (because it is a
non-cash expense) and non-recurring items as explained below.
The following reconciliation of net (loss) income to Adjusted EBITDA for the periods presented:
Venus Concept Inc.
Reconciliation of Net loss to Non-GAAP Adjusted EBITDA
|
Three Months Ended June
30,
|
Six Months Ended June 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Reconciliation of net loss to adjusted EBITDA
|
(in thousands)
|
(in thousands)
|
||||||||||||||
|
Net loss
|
$
|
(7,321
|
)
|
$
|
(10,512
|
)
|
$
|
(16,944
|
)
|
$
|
(19,148
|
)
|
||||
|
Foreign exchange loss (gain)
|
(178
|
)
|
2,370
|
(530
|
)
|
2,375
|
||||||||||
|
(Gain) loss on disposal of subsidiaries
|
(1
|
)
|
—
|
76
|
—
|
|||||||||||
|
Finance expenses
|
1,553
|
1,034
|
3,061
|
1,957
|
||||||||||||
|
Income tax expense (benefit)
|
189
|
(18
|
)
|
424
|
254
|
|||||||||||
|
Depreciation and amortization
|
1,010
|
1,111
|
2,032
|
2,212
|
||||||||||||
|
Stock-based compensation expense
|
369
|
558
|
850
|
1,001
|
||||||||||||
|
Other adjustments (1)
|
412
|
—
|
1,330
|
—
|
||||||||||||
|
Adjusted EBITDA
|
$
|
(3,967
|
)
|
$
|
(5,457
|
)
|
$
|
(9,701
|
)
|
$
|
(11,349
|
)
|
||||
(1) For the three and six months ended June 30, 2023, the other adjustments primarily represent restructuring activities designed to improve the
Company's operations and cost structure.